Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 41Carcinoma, Non-Small-Cell Lung 27Colorectal Neoplasms 17Neoplasms 13Prostatic Neoplasms 11Nasopharyngeal Carcinoma 11Lung Neoplasms 11Carcinoma, Hepatocellular 11Multiple Myeloma 9Leukemia, Myeloid, Acute 9Stomach Neoplasms 8Small Cell Lung Carcinoma 8Ovarian Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Rectal Neoplasms 7Esophageal Neoplasms 7Triple Negative Breast Neoplasms 6Pancreatic Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 6Neoplasm Metastasis 6Esophageal Squamous Cell Carcinoma 6Uterine Cervical Neoplasms 5Recurrence 5Glioblastoma 5Colonic Neoplasms 5Carcinoma, Renal Cell 5Brain Neoplasms 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Lymphoma, Follicular 4

Interventions

Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × Giant Cell Tumor of Bone × Clear all
NCT05813665 2023-04-19

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

Shanghai JMT-Bio Inc.

Phase 3 Not yet recruiting
146 enrolled

Giant Cell Tumor of Bone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡